Cargando…
Triptans in clinical practice: the basic scientist’s point of view
Since the observation that sumatriptan, the first triptan to be synthetized as a specific antimigraine compound, was able to block neurogenic inflammation (NI) in intra– and extracranial rat tissues, the experimental model for NI development has been used to predict the efficacy in aborting migraine...
Autor principal: | Buzzi, M. Gabriella |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer-Verlag
2001
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3451833/ http://dx.doi.org/10.1007/s101940170018 |
Ejemplares similares
-
Triptans: the experience of a clinical pharmacologist in clinical practice
por: Pini, Luigi Alberto, et al.
Publicado: (2001) -
Clinical experience with triptans
por: Zanchin, Giorgio, et al.
Publicado: (2001) -
Up to date on the use of triptans for child and adolescent migraine: state of the art
por: Calderoni, Dario, et al.
Publicado: (2001) -
All triptans are not the same
por: Rapoport, Alan M., et al.
Publicado: (2001) -
Success and failure of triptans
por: Saxena, Pramod R., et al.
Publicado: (2001)